- Home
- NDMO vs AUTL Comparison
NDMO vs AUTL Comparison
Compare NDMO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- AUTL
- Stock Information
- Founded
- NDMO 2019
- AUTL 2014
- Country
- NDMO United States
- AUTL United Kingdom
- Employees
- NDMO N/A
- AUTL 463
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NDMO Finance
- AUTL Health Care
- Exchange
- NDMO Nasdaq
- AUTL Nasdaq
- Market Cap
- NDMO 596.2M
- AUTL 590.8M
- IPO Year
- NDMO N/A
- AUTL 2018
- Fundamental
- Price
- NDMO $10.37
- AUTL $2.22
- Analyst Decision
- NDMO
- AUTL Strong Buy
- Analyst Count
- NDMO 0
- AUTL 3
- Target Price
- NDMO N/A
- AUTL $10.20
- AVG Volume (30 Days)
- NDMO 218.6K
- AUTL 1.4M
- Earning Date
- NDMO 01-01-0001
- AUTL 03-13-2025
- Dividend Yield
- NDMO 6.75%
- AUTL N/A
- EPS Growth
- NDMO N/A
- AUTL N/A
- EPS
- NDMO N/A
- AUTL N/A
- Revenue
- NDMO N/A
- AUTL $10,091,000.00
- Revenue This Year
- NDMO N/A
- AUTL $851.83
- Revenue Next Year
- NDMO N/A
- AUTL $264.18
- P/E Ratio
- NDMO N/A
- AUTL N/A
- Revenue Growth
- NDMO N/A
- AUTL 82.71
- 52 Week Low
- NDMO $8.99
- AUTL $2.07
- 52 Week High
- NDMO $11.24
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- NDMO 57.84
- AUTL 38.18
- Support Level
- NDMO $10.08
- AUTL $2.18
- Resistance Level
- NDMO $10.25
- AUTL $2.38
- Average True Range (ATR)
- NDMO 0.11
- AUTL 0.16
- MACD
- NDMO 0.05
- AUTL 0.01
- Stochastic Oscillator
- NDMO 100.00
- AUTL 7.94
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.